Monday, April 29, 2013

Confidential Reviews of Whistleblower Reward Lawsuits Can Protect The Whistleblower While a Case is Being Reviewed by Confidential Whistleblower Reward Lawyer Jason S. Coomer

Confidential Reviews of Whistleblower Reward Lawsuits Can Protect The Whistleblower While a Case is Being Reviewed by Confidential Whistleblower Reward Lawyer Jason S. Coomer

Whistleblower Reward Lawsuits are the most effective method for identifying and preventing large scale fraud against the government, in financial markets, and in large corporations.  By protecting a whistleblower's identity through the review process, a whistleblower reward lawyer can help protect the whistleblower through the review process and often determine if there is a viable case prior to ever exposing the whistleblower's identity.  If you are a person with special knowledge of significant fraud and corrupt practices, and are interested in learning more about a confidential review of a whistleblower reward case, please feel free to contact Whistleblower Reward Lawyer Jason Coomer via e-mail message or use our submission form

Health Care Fraud Whistleblowers including Medicaid Fraud Whistleblowers  and Medicare Fraud Whistleblowers Have Helped The Federal and State Governments Recover Billions of Dollars and Have Received Large Financial Rewards For Exposing Health Care Fraud

Health Care Whistleblower Reward Lawsuits are the most effective method for identifying and preventing large scale health care fraud against the government.  As such, the United States and several states have enacted health care whistleblower reward laws that harness the power of economic incentives by offering large monetary rewards to whistleblowers that properly report significant fraud.  As a health care whistleblower reward lawyer, Jason Coomer works with whistleblowers to confidentially gather information regarding several different types of health care whistleblower rewards including Medicare fraud whistleblower reward lawsuits and Medicaid fraud whistleblower reward lawsuits.


Procurement Fraud Whistleblowers, Government Contractor Fraud Whistleblowers, and Defense Contractor False Certification Whistleblowers With Original Evidence of Procurement Fraud, Defense Contractor Fraud, or Other Government Contractor Fraud Can File Qui Tam Government Contractor Fraud Whistleblower Lawsuits and Receive Large Rewards

Whistleblower Reward Lawsuits also include Qui Tam Procurement Fraud Whistleblower Reward Lawsuits and Qui Tam Government Contractor Fraud Whistleblower Reward Lawsuits. These qui tam government contractor fraud lawsuits were used during the Civil War against defense contractors and war profiteers that were defrauding the United States Government.  To learn more about qui tam government contractor whistleblower reward lawsuits and procurement fraud whistleblower reward lawsuits, please go to the following web pages: 
 For more information on this topic, please go to the following web page: Whistleblower Reward Lawyer Whistleblower Reward Lawsuits

Sunday, April 28, 2013

SEC Charges Eli Lilly and Company with FCPA Violations; 2012-273; December 20, 2012

SEC Charges Eli Lilly and Company with FCPA Violations; 2012-273; December 20, 2012



SEC Charges Eli Lilly and Company with FCPA Violations

FOR IMMEDIATE RELEASE
2012-273

Washington, D.C., Dec. 20, 2012 — The Securities and Exchange Commission today charged Eli Lilly and Company with violations of the Foreign Corrupt Practices Act (FCPA) for improper payments its subsidiaries made to foreign government officials to win millions of dollars of business in Russia, Brazil, China, and Poland.

Additional Materials


The SEC alleges that the Indianapolis-based pharmaceutical company’s subsidiary in Russia used offshore “marketing agreements” to pay millions of dollars to third parties chosen by government customers or distributors, despite knowing little or nothing about the third parties beyond their offshore address and bank account information. These offshore entities rarely provided any services and in some instances were used to funnel money to government officials in order to obtain business for the subsidiary. Transactions with offshore or government-affiliated entities did not receive specialized or closer review for possible FCPA violations. Paperwork was accepted at face value and little was done to assess whether the terms or circumstances surrounding a transaction suggested the possibility of foreign bribery.

The SEC alleges that when the company did become aware of possible FCPA violations in Russia, Lilly did not curtail the subsidiary’s use of the marketing agreements for more than five years. Lilly subsidiaries in Brazil, China, and Poland also made improper payments to government officials or third-party entities associated with government officials. Lilly agreed to pay more than $29 million to settle the SEC’s charges.

“When a parent company learns tell-tale signs of a bribery scheme involving a subsidiary, it must take immediate action to assure that the FCPA is not being violated,” said Antonia Chion, Associate Director in the SEC Enforcement Division. “We strongly caution company officials from averting their eyes from what they do not wish to see.”

Koninklijke Philips Electronics N.V. - 34-69327.pdf

Koninklijke Philips Electronics N.V. - 34-69327.pdf

SEC charged the Netherlands-based health care company with FCPA violations related to improper payments made by employees at its Polish subsidiary to health care officials in Poland. Philips agreed to pay more than $4.5 million to settle the charges. (4/5/13)

Saturday, April 27, 2013

Pharmacuetical Sales Representative Whistleblower Rewards by Pharmaceutical Sales Representative Whistleblower Lawyer Jason S. Coomer

Pharmacuetical Sales Representative Whistleblowers That Expose Mass Fraud and Illegel Kickbacks Can Obtain Large Rewards by Pharmaceutical Sales Representative Whistleblower Lawyer Jason S. Coomer

In the United States, the cost of health care continues to increase creating significant problems for many Americans and the United States Economy.  A significant cause of this increase in medical costs is healthcare fraud including illegal kickbacks, off label marketing of drugs and medications, fraudulent billing practices, and other forms of Health Care fraud.   

If you are a pharmaceutical whistleblower that is aware of fraudulent off label drug marketing practices, illegal drug kickbacks, or price fixing by a pharmaceutical marketing department or pharmaceutical company, please feel free to contact Pharmaceutical Off Label Drug Marketing Fraud Whistleblower Lawyer Jason Coomer via e-mail message.

U.S. sues Novartis over kickbacks | Reuters


Authorities said the Basel-based company for a decade lavished healthy speaking fees and "opulent" meals, including a nearly $10,000 dinner for three at the Japanese restaurant, Nobu, to induce doctors to prescribe its drugs.

They said this led to the Medicare and Medicaid programs paying millions of dollars in reimbursements based on kickback-tainted claims for medication such as hypertension drugs Lotrel and Valturna and the diabetes drug Starlix.

The charges are detailed in a whistleblower lawsuit first filed against Novartis Pharmaceuticals Corp by a former sales representative in January 2011 and which the U.S. government has now joined.
Twenty-seven U.S. states, the District of Columbia and the cities of New York and Chicago are also plaintiffs in the lawsuit, which seeks triple damages under the federal False Claims Act.

"Novartis corrupted the prescription drug dispensing process," U.S. Attorney Preet Bharara in Manhattan said in a statement. "For its investment, Novartis reaped dramatically increased profits on these drugs, and Medicare, Medicaid, and other federal healthcare programs were left holding the bag."


Health Care Fraud Whistleblowers including Medicaid Fraud Whistleblowers  and Medicare Fraud Whistleblowers Have Helped The Federal and State Governments Recover Billions of Dollars and Have Received Large Financial Rewards For Exposing Health Care Fraud

Health Care Whistleblower Reward Lawsuits are the most effective method for identifying and preventing large scale health care fraud against the government.  As such, the United States and several states have enacted health care whistleblower reward laws that harness the power of economic incentives by offering large monetary rewards to whistleblowers that properly report significant fraud.  As a health care whistleblower reward lawyer, Jason Coomer works with whistleblowers to confidentially gather information regarding several different types of health care whistleblower rewards including Medicare fraud whistleblower reward lawsuits and Medicaid fraud whistleblower reward lawsuits.

For more information on this area of law, please go to the following web pages:



If you are a pharmaceutical whistleblower that is aware of fraudulent off label drug marketing practices, illegal drug kickbacks, or price fixing by a pharmaceutical marketing department or pharmaceutical company, please feel free to contact Pharmaceutical Off Label Drug Marketing Fraud Whistleblower Lawyer Jason Coomer via e-mail message.